AbbVie (ABBV) Q1 Earnings and Revenues Beat Estimates

Core Insights - AbbVie reported quarterly earnings of $2.46 per share, exceeding the Zacks Consensus Estimate of $2.39 per share, and showing an increase from $2.31 per share a year ago, representing an earnings surprise of 2.93% [1] - The company achieved revenues of $13.34 billion for the quarter, surpassing the Zacks Consensus Estimate by 3.39% and increasing from $12.31 billion year-over-year [2] - AbbVie has consistently outperformed consensus EPS and revenue estimates over the last four quarters [2] Earnings Outlook - The future performance of AbbVie’s stock will largely depend on management's commentary during the earnings call and the trends in earnings estimate revisions [3][4] - The current consensus EPS estimate for the upcoming quarter is $3.09 on revenues of $14.8 billion, and for the current fiscal year, it is $12.20 on revenues of $59.58 billion [7] Industry Context - The Large Cap Pharmaceuticals industry, to which AbbVie belongs, is currently ranked in the top 21% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - The performance of AbbVie’s stock may also be influenced by the overall industry outlook and trends [8] Competitor Insights - Eli Lilly, a competitor in the same industry, is expected to report quarterly earnings of $3.52 per share, reflecting a year-over-year increase of 36.4%, with revenues anticipated to be $12.62 billion, up 43.9% from the previous year [9][10]